Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.36 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.35 |
| ▸ | FLT4 | P35916 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776946 | 0.92 | HRH3 (0.44) | HRH3KDRNUDT1CDK2CDK1 | |
| SCHEMBL2778635 | 0.85 | DRD2 (0.44) | HRH3DRD2DRD4APPCA12 | |
| SCHEMBL12972302 | 0.82 | RAB9A (0.51) | HRH3DRD2DRD4APPNUDT1 | |
| SCHEMBL2777117 | 0.82 | MEN1 (0.56) | HRH3DRD2DRD4KDRCA12 | |
| SCHEMBL2777149 | 0.78 | HRH3 (0.41) | HRH3DRD2DRD4APPKDR | |
| SCHEMBL2435821 | 0.78 | AURKA (0.47) | KDRNUDT1CDK2CDK1CDK8 | |
| SCHEMBL4533554 | 0.73 | CDK2 (0.52) | DRD2DRD4KDRCDK2CDC7 | |
| SCHEMBL14553221 | 0.73 | HRH3 (0.44) | HRH3DRD2DRD4APPS1PR1 | |
| SCHEMBL2777158 | 0.73 | DRD2 (0.43) | HRH3DRD2DRD4APPCA12 | |
| SCHEMBL24229628 | 0.73 | RIPK1 (0.40) | KDRNUDT1FLT1FLT4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | HRH3 526/4885DRD2 3657/4885DRD4 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.